Cantor Fitzgerald Reiterates Aclaris Therapeutis (ACRS) at Overweight, "Still a Lot of Value to be Unlocked in ACRS's Pipeline"
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $38.00 price target on Aclaris Therapeutis (NASDAQ: ACRS), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
